Trial · NCT02270242
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
NCT02270242, Phase 4, Completed, Icahn School of Medicine at Mount Sinai; results first posted 2020-08-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention. Trials, record NCT02270242. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02270242
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
- NCT number
- NCT02270242
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 9,006 participants, actual
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Conditions
- Cardiovascular Disease, Interventional Cardiology
- Interventions
- Aspirin, Placebo, ticagrelor
- First posted
- 2014-10-21
- Last updated
- 2021-01-13
- Results first posted
- 2020-08-19
- Limitations and caveats
Limitations include lack of power to detect differences in the risk of important yet rare clinical events, e.g stent thrombosis and stroke; and trial may not be generalizable to all patients undergoing PCI due to high risk criteria.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With BARC Type 2, 3, or 5 | 12 months after randomization | Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). |
| Secondary | Number of Participants With Ischemic Episode | 12 months after randomization | Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With BARC Type 2, 3, or 5 | 12 months after randomization | Data for the intention-to-treat population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Ischemic Episode | 12 months after randomization | data for the per-protocol population , i.e., the participants who underwent randomization and had no major deviations from the protocol. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With BARC Type 2, 3, or 5 | Placebo + Ticagrelor | 141 | Participants | ||
| Number of Participants With BARC Type 2, 3, or 5 | Aspirin + Ticagrelor | 250 | Participants | ||
| Number of Participants With Ischemic Episode | Placebo + Ticagrelor | 135 | Participants | ||
| Number of Participants With Ischemic Episode | Aspirin + Ticagrelor | 137 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo + Ticagrelor | 3,555 | |
| Overall Study | STARTED | Aspirin + Ticagrelor | 3,564 | |
| Overall Study | COMPLETED | Placebo + Ticagrelor | 3,496 | |
| Overall Study | COMPLETED | Aspirin + Ticagrelor | 3,511 | |
| Overall Study | NOT COMPLETED | Placebo + Ticagrelor | 59 | |
| Overall Study | NOT COMPLETED | Aspirin + Ticagrelor | 53 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Myocardial Infarction | Cardiac disorders | Placebo + Ticagrelor | 95 | 3,524 | |
| serious | Myocardial Infarction | Cardiac disorders | Aspirin + Ticagrelor | 97 | 3,515 | |
| serious | Ischemic Stroke | Vascular disorders | Placebo + Ticagrelor | 18 | 3,524 | |
| serious | Ischemic Stroke | Vascular disorders | Aspirin + Ticagrelor | 10 | 3,515 | |
| serious | Stent Thrombosis, definite or probable | Injury, poisoning and procedural complications | Placebo + Ticagrelor | 14 | 3,524 | |
| serious | Stent Thrombosis, definite or probable | Injury, poisoning and procedural complications | Aspirin + Ticagrelor | 20 | 3,515 | |
| serious | BARC 235 | Vascular disorders | Placebo + Ticagrelor | 141 | 3,555 | |
| serious | BARC 235 | Vascular disorders | Aspirin + Ticagrelor | 250 | 3,564 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo + Ticagrelor | 34 | 3,524 |
| Total, all-cause mortality | Aspirin + Ticagrelor | 45 | 3,515 |
| Total, other adverse events | Placebo + Ticagrelor | 0 | 3,555 |
| Total, other adverse events | Aspirin + Ticagrelor | 0 | 3,564 |
| Total, serious adverse events | Placebo + Ticagrelor | 262 | 3,555 |
| Total, serious adverse events | Aspirin + Ticagrelor | 370 | 3,564 |
Source ClinicalTrials.gov
Papers38
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Placebo + Ticagrelor vs Aspirin + Ticagrelor: Number of Participants With Ischemic Episode | Trial comparisons |
| Placebo + Ticagrelor vs Aspirin + Ticagrelor: Number of Participants With BARC Type 2, 3, or 5 | Trial comparisons |
| Placebo + Ticagrelor vs Aspirin + Ticagrelor: deaths from any cause | Trial comparisons |
| Placebo + Ticagrelor vs Aspirin + Ticagrelor: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02270242
GET https://conductscience.org/api/trials/v1/NCT02270242/papers?page=2